Analysis of clinical use effects and patient feedback of Pimitespib in Hainan Hospital

Pimitespib (Pimitespib) is an oral HSP90 inhibitor. It is mainly used to treat advanced or recurrent gastric cancer and other refractory solid tumors. It has been marketed in Japan. In recent years, with the introduction of a variety of innovative drugs in Hainan's Boao Lecheng Pilot Zone, pimoteb has also taken the lead in clinical use in some Hainan hospitals, providing a new treatment approach for domestic late-stage patients. The introduction of this drug is of great significance, especially for patients who have failed standard treatments and lack other effective options.

Many hospitals in Hainan have used pimitibib to treat patients with advanced gastric cancer, sarcoma and some rare tumors in the real world. Data show that the drug can stabilize the condition or shrink tumors in some patients. After some patients with gastric cancer took 1 to 2 courses of treatment (about 4 to 8 weeks), imaging examinations showed that the tumor volume was significantly reduced, the level of tumor markers dropped, and symptoms such as abdominal distension and difficulty eating were relieved. For patients who have failed multiple lines of therapy, pimetibi shows potential in delaying disease progression and improving quality of life.

Based on patient feedback, the oral administration method of pimetibi is convenient and has good compliance. Most patients reported mild to moderate adverse reactions such as diarrhea, fatigue, and loss of appetite in the early stages of treatment, but most were able to continue treatment after symptomatic treatment. Some patients mentioned that their physical strength recovered and their symptoms were relieved within 2 to 4 weeks after taking the medicine, and they expressed a positive attitude towards the treatment results. At the same time, clinicians also emphasize that elderly patients or those with poor underlying conditions need to closely monitor liver and kidney function and electrolyte changes during medication.

Overall, the clinical use of pimetibi in Hainan Hospital has brought new treatment options to some advanced patients. Its real-world efficacy is consistent with clinical trial results and it is well tolerated. In the future, with the accumulation of more clinical data and its exploration in more cancer types and combination treatments, pimetibi is expected to be more widely used in China. At the same time, early implementation of molecular testing and scientific selection of indications will help improve patient benefits and further maximize the clinical value of the drug.

Reference link:https://www.drugs.com

xa0